Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 6 art units • 8 examiners • 0 of 9 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Askbio Inc. is managing 9 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 8 distinct examiners, indicating that most applications are being reviewed by different individuals. This arrangement suggests that the legal team must manage 8 separate examiner relationships to advance the current portfolio.
The 9 pending actions are located across 6 distinct art units. This variety of art units indicates that the company's Biotechnology & Pharmaceuticals innovations are being evaluated by several different technical divisions at the patent office. Practitioners must navigate the specific procedural and technical standards of 6 different art units to successfully prosecute the filings.
HUMPHRIES, NICHOLAS ADAM is the busiest examiner for this portfolio, with 2 pending office actions. As the only examiner with 2 actions, this individual represents the highest point of concentration in the portfolio. However, with 8 distinct examiners involved in total, the majority of the 9 pending office actions still require individual attention and tailored strategies.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (11%) |
| Double-patenting + other | 2 (22%) |
| Multi-statute (no §101) | 6 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUMPHRIES, NICHOLAS ADAM | 2 | 36.1% | +75.9% |
| CONNORS, ALEXANDRA F | 1 | 23.9% | +45.4% |
| BEHARRY, ZANNA MARIA | 1 | 24.7% | +56.4% |
| KASHYAP, ESHA PRAKASH | 1 | 100.0% | +0.0% |
| VIJAYARAGHAVAN, JAGAMYA NMN | 1 | 62.5% | +49.3% |
| O'NEILL, MARISOL ANN | 1 | 53.1% | +68.2% |
| LAFAVE, ELIZABETH ROSE | 1 | 62.5% | +45.4% |
| SALVOZA, M FRANCO G | 1 | 68.4% | +30.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17797633 | METHOD OF TREATING GENE THERAPY ASSOCIATED TOXICITY WITH ANTIBIOTICS | O'NEILL, MARISOL ANN | 60d overdue |
| 18019421 | METHODS OF TREATING CARDIAC DISORDERS AND CONGESTIVE HEART FAILURE AND ADMINISTERING AAV VECTORS | VIJAYARAGHAVAN, JAGAMYA NMN | 32d overdue |
| 18850414 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE | CONNORS, ALEXANDRA F | — |
| 18572668 | REGULATORY NUCLEIC ACID SEQUENCES | BEHARRY, ZANNA MARIA | — |
| 18557475 | CANNULA ASSEMBLY | KASHYAP, ESHA PRAKASH | — |
| 18286709 | RATIONAL POLYPLOID AAV VIRIONS THAT CROSS THE BLOOD BRAIN BARRIER AND ELICIT REDUCED HUMORAL RESPONSE | HUMPHRIES, NICHOLAS ADAM | — |
| 17787898 | METHOD FOR IDENTIFYING REGULATORY ELEMENTS | LAFAVE, ELIZABETH ROSE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17797633 | METHOD OF TREATING GENE THERAPY ASSOCIATED TOXICITY WITH ANTIBIOTICS | O'NEILL, MARISOL ANN | 60d overdue |
| 18019421 | METHODS OF TREATING CARDIAC DISORDERS AND CONGESTIVE HEART FAILURE AND ADMINISTERING AAV VECTORS | VIJAYARAGHAVAN, JAGAMYA NMN | 32d overdue |
| 17293861 | VECTORS COMPRISING A NUCLEIC ACID ENCODING LYSOSOMAL ENZYMES FUSED TO A LYSOSOMAL TARGETING SEQUENCE | SALVOZA, M FRANCO G | 17d overdue |
| 18850414 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE | CONNORS, ALEXANDRA F | — |
| 18572668 | REGULATORY NUCLEIC ACID SEQUENCES | BEHARRY, ZANNA MARIA | — |
| 18286709 | RATIONAL POLYPLOID AAV VIRIONS THAT CROSS THE BLOOD BRAIN BARRIER AND ELICIT REDUCED HUMORAL RESPONSE | HUMPHRIES, NICHOLAS ADAM | — |
| 17907229 | INDUCIBLE PROMOTER FOR VIRAL VECTOR PRODUCTION | HUMPHRIES, NICHOLAS ADAM | — |
| 17787898 | METHOD FOR IDENTIFYING REGULATORY ELEMENTS | LAFAVE, ELIZABETH ROSE | — |
| Art Unit | Apps |
|---|---|
| 1633 | 3 |
| 1631 | 2 |
| 1632 | 1 |
| 3783 | 1 |
| 1684 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18850414 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE | CONNORS, ALEXANDRA F | 1633 | §103§112 | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18572668 | REGULATORY NUCLEIC ACID SEQUENCES | BEHARRY, ZANNA MARIA | 1632 | §102§112DP | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18557475 | CANNULA ASSEMBLY | KASHYAP, ESHA PRAKASH | 3783 | §102§103 | Final Rejection | — | Pending | Oct 26, 2023 |
| 18286709 | RATIONAL POLYPLOID AAV VIRIONS THAT CROSS THE BLOOD BRAIN BARRIER AND ELICIT REDUCED HUMORAL RESPONSE | HUMPHRIES, NICHOLAS ADAM | 1631 | §102§103§112 | Non-Final OA | — | Pending | Oct 12, 2023 |
| 18019421 | METHODS OF TREATING CARDIAC DISORDERS AND CONGESTIVE HEART FAILURE AND ADMINISTERING AAV VECTORS | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §102§103§112 | Final Rejection | 32d overdue | Pending | Feb 02, 2023 |
| 17907229 | INDUCIBLE PROMOTER FOR VIRAL VECTOR PRODUCTION | HUMPHRIES, NICHOLAS ADAM | 1631 | §102§103§112DP | Final Rejection | — | Pending | Sep 23, 2022 |
| 17797633 | METHOD OF TREATING GENE THERAPY ASSOCIATED TOXICITY WITH ANTIBIOTICS | O'NEILL, MARISOL ANN | 1633 | §103§112 | Non-Final OA | 60d overdue | Pending | Aug 04, 2022 |
| 17787898 | METHOD FOR IDENTIFYING REGULATORY ELEMENTS | LAFAVE, ELIZABETH ROSE | 1684 | §103§112 | Non-Final OA | — | Pending | Jun 21, 2022 |
| 17293861 | VECTORS COMPRISING A NUCLEIC ACID ENCODING LYSOSOMAL ENZYMES FUSED TO A LYSOSOMAL TARGETING SEQUENCE | SALVOZA, M FRANCO G | 1672 | §112Other | Non-Final OA | 17d overdue | Pending | May 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial